Related Experiment Videos
[Neoadjuvant therapy for operable breast-cancer].
Amelia Insa1, Isabel Chirivella, Ana Lluch
1Servicio de Hematología y Oncología Médica, Hospital Clínico Universitario de Valencia, Universidad de Valencia, Valencia, Spain.
Medicina Clinica
|March 11, 2006
Summary
Neoadjuvant systemic treatment provides survival benefits similar to adjuvant therapy and increases breast-conserving surgery rates. This approach helps personalize breast cancer treatment by evaluating tumor response to chemotherapy.
Area of Science:
- Oncology
- Clinical Trials
- Cancer Therapeutics
Context:
- Preoperative (neoadjuvant) systemic treatment is the initial therapy post-diagnosis, with further treatment planned.
- Randomized controlled trials confirm neoadjuvant therapy's efficacy.
- Neoadjuvant therapy is increasingly recognized for its role in personalized cancer care.
Purpose:
- To review the benefits and challenges of neoadjuvant systemic treatment in breast cancer.
- To highlight its role in improving surgical outcomes and personalizing treatment strategies.
- To identify areas needing further research, including predictive markers and optimal treatment sequencing.
Summary:
- Neoadjuvant systemic treatment offers equivalent disease-free and overall survival benefits compared to adjuvant systemic treatment.
- It enhances the rate of breast-conserving surgery and allows for in vivo assessment of chemotherapy response.
- This modality enables individualized treatment based on tumor biology and response.
Impact:
- Neoadjuvant therapy represents a significant advancement in breast cancer management, promoting personalized medicine.
- It improves surgical options and provides valuable data on treatment effectiveness.
- Further research is needed to optimize marker selection and integrate surgical and radiotherapy planning.